| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
|
| Targets |
PI3K; Akt
|
|---|---|
| ln Vitro |
α-Linolenic acid converses into the longer chain fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)[1].
|
| ln Vivo |
In mice, α-Linolenic acid (50, 100, or 250 mg/kg; for 10 days) completely inhibits collagen- and adrenaline-induced thrombosis at 250 mg/kg[1]. Rats weighing 250–300 g have less A-V thrombus formation when given 35, 70, or 175 mg/kg of α-Linolenic acid[1]. In rats, α-Linolenic acid (70 or 175 mg/kg) inhibits collagen stimulated platelet aggregation[1].
|
| Animal Protocol |
Mice weighing at 18 ~ 22 g[1]
50, 100, 250 mg/kg For 10 days |
| References |
| Molecular Formula |
C₁₈H₃₀O₂
|
|---|---|
| Molecular Weight |
278.43
|
| CAS # |
463-40-1
|
| Related CAS # |
463-40-1
|
| Appearance |
Liquid
|
| SMILES |
CC/C=C\C/C=C\C/C=C\CCCCCCCC(=O)O
|
| InChi Key |
DTOSIQBPPRVQHS-PDBXOOCHSA-N
|
| InChi Code |
InChI=1S/C18H30O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h3-4,6-7,9-10H,2,5,8,11-17H2,1H3,(H,19,20)/b4-3-,7-6-,10-9-
|
| Chemical Name |
(9Z,12Z,15Z)-octadeca-9,12,15-trienoic acid
|
| Synonyms |
αLinolenic acid α Linolenic acid
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Ethanol: ~100 mg/mL (~359.2 mM)
DMSO: ~100 mg/mL (~359.2 mM) H2O: <0.1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.98 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.98 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.98 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5916 mL | 17.9578 mL | 35.9157 mL | |
| 5 mM | 0.7183 mL | 3.5916 mL | 7.1831 mL | |
| 10 mM | 0.3592 mL | 1.7958 mL | 3.5916 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT04481724 | Active Recruiting |
Dietary Supplement: placebo Dietary Supplement: gamma- linolenic acid |
Weight Trajectory | Virta Health | July 22, 2020 | |
| NCT03025620 | Completed | Dietary Supplement: Rapeseed oil Dietary Supplement: Sunflower oil |
Cardiovascular Diseases Inflammation |
Assistance Publique - Hôpitaux de Paris |
November 2006 | |
| NCT00694083 | Completed | Drug: Ridaforolimus | Neoplasm | Assistance Publique - Hôpitaux de Paris |
November 2006 | Phase 1 |
| NCT02433977 | Completed | Drug: Sodium Nitrate Drug: Sodium Nitrite |
Asthma | Gladwin, Mark, MD | September 2015 | Phase 2 |
| NCT00004420 | Completed | Drug: gamma-Linolenic acid |
Juvenile Rheumatoid Arthritis | FDA Office of Orphan ProductsDevelopment |
September 1994 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
